Lipoprotein-associated ApoC-III [apoB, apoAI, Lp(a)] levels have been associated to coronary artery disease (CAD) risk in the EPIC-Norfolk prospective population study including 25,663 subjects [15]. Here, APOB is linked to coronary artery disorder.